JP2011527340A - 経口活性クルクミノイド化合物 - Google Patents
経口活性クルクミノイド化合物 Download PDFInfo
- Publication number
- JP2011527340A JP2011527340A JP2011517314A JP2011517314A JP2011527340A JP 2011527340 A JP2011527340 A JP 2011527340A JP 2011517314 A JP2011517314 A JP 2011517314A JP 2011517314 A JP2011517314 A JP 2011517314A JP 2011527340 A JP2011527340 A JP 2011527340A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- mixture
- compounds
- curcumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 80
- 229930153442 Curcuminoid Natural products 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 28
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 16
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 111
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 24
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 14
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 7
- 150000001412 amines Chemical class 0.000 claims description 6
- 229910052810 boron oxide Inorganic materials 0.000 claims description 6
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 6
- JKWMSGQKBLHBQQ-UHFFFAOYSA-N diboron trioxide Chemical compound O=BOB=O JKWMSGQKBLHBQQ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- LGQXXHMEBUOXRP-UHFFFAOYSA-N tributyl borate Chemical compound CCCCOB(OCCCC)OCCCC LGQXXHMEBUOXRP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- 229930194542 Keto Natural products 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 150000002085 enols Chemical class 0.000 claims description 3
- 125000000468 ketone group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 150000003335 secondary amines Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 abstract description 41
- 235000020669 docosahexaenoic acid Nutrition 0.000 abstract description 23
- 235000020673 eicosapentaenoic acid Nutrition 0.000 abstract description 23
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 abstract description 23
- 229960005135 eicosapentaenoic acid Drugs 0.000 abstract description 23
- 229940090949 docosahexaenoic acid Drugs 0.000 abstract description 22
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 abstract description 21
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 77
- 239000000203 mixture Substances 0.000 description 48
- 239000000243 solution Substances 0.000 description 41
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 39
- 235000012754 curcumin Nutrition 0.000 description 38
- 229940109262 curcumin Drugs 0.000 description 38
- 239000004148 curcumin Substances 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 239000003814 drug Substances 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- 239000012267 brine Substances 0.000 description 18
- 239000000651 prodrug Substances 0.000 description 18
- 229940002612 prodrug Drugs 0.000 description 18
- 229910052938 sodium sulfate Inorganic materials 0.000 description 18
- 235000011152 sodium sulphate Nutrition 0.000 description 18
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 210000004556 brain Anatomy 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 239000003480 eluent Substances 0.000 description 14
- -1 phosphorus halide Chemical class 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 230000003197 catalytic effect Effects 0.000 description 12
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 12
- 150000002500 ions Chemical class 0.000 description 12
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- SBHCLVQMTBWHCD-YECCEMIOSA-N (2z)-icosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=C\C=C/C(O)=O SBHCLVQMTBWHCD-YECCEMIOSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 9
- DVSZKTAMJJTWFG-CPIIABRBSA-N (2z)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=C\C=C/C(O)=O DVSZKTAMJJTWFG-CPIIABRBSA-N 0.000 description 8
- 244000163122 Curcuma domestica Species 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 8
- DKICPHDTXJUJIZ-UHFFFAOYSA-N [4-[7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-methoxyphenyl] icosa-2,4,6,8,10-pentaenoate Chemical compound C1=C(OC)C(OC(=O)C=CC=CC=CC=CC=CCCCCCCCCC)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(O)C(OC)=C1 DKICPHDTXJUJIZ-UHFFFAOYSA-N 0.000 description 7
- 235000003373 curcuma longa Nutrition 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- OJFGQVZAISEIPG-UHFFFAOYSA-N 1,7-bis(3,4-dihydroxyphenyl)hepta-1,6-diene-3,5-dione Chemical compound C1=C(O)C(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(O)C(O)=C1 OJFGQVZAISEIPG-UHFFFAOYSA-N 0.000 description 6
- ITSBOLXWPMAPHR-UHFFFAOYSA-N [4-[7-(4-hydroxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-methoxyphenyl] docosa-2,4,6,8,10,12-hexaenoate Chemical compound C1=C(OC)C(OC(=O)C=CC=CC=CC=CC=CC=CCCCCCCCCC)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(O)C(OC)=C1 ITSBOLXWPMAPHR-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 6
- 235000012141 vanillin Nutrition 0.000 description 6
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 6
- UJEUWIMYKLJGLQ-UHFFFAOYSA-N (4-formyl-2-methoxyphenyl) icosa-2,4,6,8,10-pentaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC(=O)OC1=CC=C(C=O)C=C1OC UJEUWIMYKLJGLQ-UHFFFAOYSA-N 0.000 description 5
- 235000003392 Curcuma domestica Nutrition 0.000 description 5
- UAZHWIXFOFAWEN-UHFFFAOYSA-N [4-[7-(4-icosa-2,4,6,8,10-pentaenoyloxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-methoxyphenyl] icosa-2,4,6,8,10-pentaenoate Chemical compound C1=C(OC)C(OC(=O)C=CC=CC=CC=CC=CCCCCCCCCC)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(OC(=O)C=CC=CC=CC=CC=CCCCCCCCCC)C(OC)=C1 UAZHWIXFOFAWEN-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 150000004671 saturated fatty acids Chemical class 0.000 description 5
- 235000013976 turmeric Nutrition 0.000 description 5
- YBWDSTYVWLQWIB-UHFFFAOYSA-N (4-formyl-2-methoxyphenyl) docosa-2,4,6,8,10,12-hexaenoate Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(=O)OC1=CC=C(C=O)C=C1OC YBWDSTYVWLQWIB-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 235000003441 saturated fatty acids Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003880 polar aprotic solvent Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MGNKYFZJRPFIHG-UHFFFAOYSA-N [2-hydroxy-4-[7-(3-hydroxy-4-icosa-2,4,6,8,10-pentaenoyloxyphenyl)-3,5-dioxohepta-1,6-dienyl]phenyl] icosa-2,4,6,8,10-pentaenoate Chemical compound C1=C(O)C(OC(=O)C=CC=CC=CC=CC=CCCCCCCCCC)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(OC(=O)C=CC=CC=CC=CC=CCCCCCCCCC)C(O)=C1 MGNKYFZJRPFIHG-UHFFFAOYSA-N 0.000 description 2
- QJJYBDSVYMWDHN-UHFFFAOYSA-N [4-[7-(4-docosa-2,4,6,8,10,12-hexaenoyloxy-3-methoxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-methoxyphenyl] docosa-2,4,6,8,10,12-hexaenoate Chemical compound C1=C(OC)C(OC(=O)C=CC=CC=CC=CC=CC=CCCCCCCCCC)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(OC(=O)C=CC=CC=CC=CC=CC=CCCCCCCCCC)C(OC)=C1 QJJYBDSVYMWDHN-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940000640 docosahexaenoate Drugs 0.000 description 2
- 229940066279 eicosapentaenoate Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- FFRFJIZJLZXEJX-YPCIICBESA-N 1-(3,4-Dihydroxyphenyl)-7-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(O)C(O)=CC=2)=C1 FFRFJIZJLZXEJX-YPCIICBESA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- HPGQVGVZXHYHCT-ZKFUEKSZSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(Oc1ccc(/C=C/C(CC(/C=C/c(cc2)cc(OC)c2O)=O)=O)cc1OC)=O Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(Oc1ccc(/C=C/C(CC(/C=C/c(cc2)cc(OC)c2O)=O)=O)cc1OC)=O HPGQVGVZXHYHCT-ZKFUEKSZSA-N 0.000 description 1
- HHWXMSRABKZCJQ-RXGMNIJBSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(Oc(ccc(/C=C/C(CC(/C=C/c(cc1)cc(O)c1O)=O)=O)c1)c1O)=O Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(Oc(ccc(/C=C/C(CC(/C=C/c(cc1)cc(O)c1O)=O)=O)c1)c1O)=O HHWXMSRABKZCJQ-RXGMNIJBSA-N 0.000 description 1
- ANOSVLOPUSOYLF-SNTYNKHHSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(Oc1ccc(/C=C/C(CC(/C=C/c(cc2OC)ccc2O)=O)=O)cc1OC)=O Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(Oc1ccc(/C=C/C(CC(/C=C/c(cc2OC)ccc2O)=O)=O)cc1OC)=O ANOSVLOPUSOYLF-SNTYNKHHSA-N 0.000 description 1
- KVABQILRFSQPOB-OMMHLYHPSA-N CC/C=C\C/C=C\CCC(C/C=C\C/C=C\C/C=C\CCC(Oc1ccc(/C=C/C(CC(/C=C/c(cc2)cc(OC)c2O)=O)=O)cc1OC)=O)=C Chemical compound CC/C=C\C/C=C\CCC(C/C=C\C/C=C\C/C=C\CCC(Oc1ccc(/C=C/C(CC(/C=C/c(cc2)cc(OC)c2O)=O)=O)cc1OC)=O)=C KVABQILRFSQPOB-OMMHLYHPSA-N 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000000476 Fatty Acid Transport Proteins Human genes 0.000 description 1
- 108010055870 Fatty Acid Transport Proteins Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- INQBRYGAQFGNPF-UHFFFAOYSA-N [4-[7-(3,4-dihydroxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-hydroxyphenyl] icosa-2,4,6,8,10-pentaenoate Chemical compound C1=C(O)C(OC(=O)C=CC=CC=CC=CC=CCCCCCCCCC)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(O)C(O)=C1 INQBRYGAQFGNPF-UHFFFAOYSA-N 0.000 description 1
- XXUKDLQSJSXPNT-UHFFFAOYSA-N [4-[7-(4-docosa-2,4,6,8,10,12-hexaenoyloxy-3-hydroxyphenyl)-3,5-dioxohepta-1,6-dienyl]-2-hydroxyphenyl] docosa-2,4,6,8,10,12-hexaenoate Chemical compound C1=C(O)C(OC(=O)C=CC=CC=CC=CC=CC=CCCCCCCCCC)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=C(OC(=O)C=CC=CC=CC=CC=CC=CCCCCCCCCC)C(O)=C1 XXUKDLQSJSXPNT-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- MXGYVBOZRLQICP-VUSYVUDMSA-N chembl494826 Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)\C=C(/O)\C=C\C1=CC=C(O)C(OC)=C1 MXGYVBOZRLQICP-VUSYVUDMSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- VEKIZRLWPXYFMW-UHFFFAOYSA-N hepta-1,6-diene-3,5-dione Chemical compound C=CC(=O)CC(=O)C=C VEKIZRLWPXYFMW-UHFFFAOYSA-N 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000007153 proteostasis deficiencies Diseases 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
- C07C67/293—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
- C07C69/587—Monocarboxylic acid esters having at least two carbon-to-carbon double bonds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1641/CHE/2008 | 2008-07-07 | ||
| IN1641CH2008 | 2008-07-07 | ||
| PCT/IN2009/000382 WO2010004579A2 (en) | 2008-07-07 | 2009-07-06 | Orally active curcuminoid compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011527340A true JP2011527340A (ja) | 2011-10-27 |
| JP2011527340A5 JP2011527340A5 (OSRAM) | 2012-08-23 |
Family
ID=41507515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517314A Pending JP2011527340A (ja) | 2008-07-07 | 2009-07-06 | 経口活性クルクミノイド化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8680143B2 (OSRAM) |
| EP (1) | EP2294049A4 (OSRAM) |
| JP (1) | JP2011527340A (OSRAM) |
| CN (1) | CN102131765A (OSRAM) |
| AU (1) | AU2009269530A1 (OSRAM) |
| WO (1) | WO2010004579A2 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015186144A2 (en) * | 2014-06-07 | 2015-12-10 | Laila Pharmaceuticals Pvt. Ltd. | Method of inhibition of beta-secretase by using bis-o-demethylcurcumin for the prevention, management and treatment of neurodegenerative diseases |
| US10085951B2 (en) | 2014-12-11 | 2018-10-02 | Designs For Health, Inc. | Curcuminoid formulations and related methods of treatment |
| US11135185B2 (en) | 2018-03-23 | 2021-10-05 | Merry Life Biomedical Company, Ltd. | Uses of curcumin derivative |
| CN112315953B (zh) * | 2020-11-06 | 2023-03-07 | 中国海洋大学 | 一种姜黄素酯在改善急性肾损伤制品中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031122A1 (de) * | 2002-10-01 | 2004-04-15 | Dr. André Rieks - Labor Für Enzymtechnologie Gmbh | Neue curcumin/tetrahydrocurcumin-derivate für den einsatz in kosmetika, pharmazeutika und bei der ernährung |
| WO2006117077A1 (en) * | 2005-05-03 | 2006-11-09 | Dsm Ip Assets B.V. | Aryl derivatives of curcumin, demethoxycurcumin, bisdemethoxycurcumin or curcuminisoxazolide and their use as animal feed additives |
| WO2007103435A2 (en) * | 2006-03-06 | 2007-09-13 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders |
| WO2007110168A1 (en) * | 2006-03-29 | 2007-10-04 | Dsm Ip Assets B.V. | Curcumin synthesis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2665916C (en) * | 2006-10-12 | 2015-12-08 | The Research Foundation Of The City University Of New York | Novel curcumin and tetrahydrocurcumin derivatives |
-
2009
- 2009-07-06 EP EP09794105A patent/EP2294049A4/en not_active Withdrawn
- 2009-07-06 AU AU2009269530A patent/AU2009269530A1/en not_active Abandoned
- 2009-07-06 WO PCT/IN2009/000382 patent/WO2010004579A2/en not_active Ceased
- 2009-07-06 CN CN2009801136580A patent/CN102131765A/zh active Pending
- 2009-07-06 US US13/002,588 patent/US8680143B2/en not_active Expired - Fee Related
- 2009-07-06 JP JP2011517314A patent/JP2011527340A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004031122A1 (de) * | 2002-10-01 | 2004-04-15 | Dr. André Rieks - Labor Für Enzymtechnologie Gmbh | Neue curcumin/tetrahydrocurcumin-derivate für den einsatz in kosmetika, pharmazeutika und bei der ernährung |
| WO2006117077A1 (en) * | 2005-05-03 | 2006-11-09 | Dsm Ip Assets B.V. | Aryl derivatives of curcumin, demethoxycurcumin, bisdemethoxycurcumin or curcuminisoxazolide and their use as animal feed additives |
| WO2007103435A2 (en) * | 2006-03-06 | 2007-09-13 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating alzheimer's disease and other age-related disorders |
| WO2007110168A1 (en) * | 2006-03-29 | 2007-10-04 | Dsm Ip Assets B.V. | Curcumin synthesis |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010004579A2 (en) | 2010-01-14 |
| WO2010004579A3 (en) | 2011-01-27 |
| CN102131765A (zh) | 2011-07-20 |
| EP2294049A2 (en) | 2011-03-16 |
| AU2009269530A1 (en) | 2010-01-14 |
| US8680143B2 (en) | 2014-03-25 |
| EP2294049A4 (en) | 2011-06-22 |
| US20110112190A1 (en) | 2011-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106715456B (zh) | 定向淋巴的前药 | |
| KR0141507B1 (ko) | 페닐알칸산유도체,그제조방법 및 그것을 함유하는 의약제제 | |
| AU2005295876A1 (en) | Novel curcumin analogues and uses thereof | |
| JP2019513422A (ja) | カンナビノイドプロドラッグの生合成法 | |
| US11993563B2 (en) | Solid compositions of cocrystals of cannabinoids | |
| JP2013500986A (ja) | 肝臓ｘ受容体アゴニスト | |
| JP2010150266A (ja) | 新規なクルクミン類似体およびそれらの使用 | |
| SK147097A3 (en) | Fatty acid esters as bioactive compounds | |
| HU212103B (en) | Process for preparing 4-hydroxy-tetrahydro-pyrane-2-one derivatives and their dihydroxy carboxylic acid derivatives and pharmaceutical preparations containing them | |
| CN1774252A (zh) | 丙戊酸的磷脂衍生物及其混合物 | |
| JP2011527340A (ja) | 経口活性クルクミノイド化合物 | |
| JP2020002165A (ja) | ジピコリルアミン誘導体及びそれらの薬学的使用 | |
| JP2003528842A (ja) | 治療化合物としての置換カルコン | |
| JP2024122966A (ja) | 芳香族化合物およびその医薬用途 | |
| WO2008062830A1 (en) | Spiroquinone compound and pharmaceutical composition | |
| CN1301987C (zh) | 7－羧基－黄酮衍生物、其制备方法和应用 | |
| CN103613568B (zh) | 一种萘托酮及其类似物的制备方法 | |
| CN1665495A (zh) | 长链不饱和氧化化合物及其在治疗、化妆品的制营养品的领域中的应用 | |
| CA2980221C (en) | Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof | |
| MC749A1 (fr) | Nouveaux dérivés fluorés des esters de l'acide phenoxy-isobutyrique et leur procédé de préparation | |
| CN116813515A (zh) | 一种姜黄素衍生物前药、其制备方法和应用 | |
| FR2849849A1 (fr) | Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies | |
| CN103260614B (zh) | 联合疗法 | |
| CN100408581C (zh) | 3-(1-烷氧基乙基)-8-乙基-2,7,12,15,18-五甲基-13-羧酸-17-丙酸、其合成方法和光动力治疗药物 | |
| FR2503140A1 (fr) | Acides biphenyl-4 oxo-4 methylene-3 butyriques, leur procede de preparation et leur utilisation comme medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120703 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120703 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131112 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20131114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140212 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140224 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140610 |